Safety Study of JTT-302 in Subjects With Low HDL-C Levels

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00748852
Recruitment Status : Completed
First Posted : September 9, 2008
Last Update Posted : February 4, 2013
Information provided by (Responsible Party):
Akros Pharma Inc.

Brief Summary:
The purpose of this study is to evaluate the safety of JTT-302 when administered for eight or 12 weeks in subjects with low HDL-C levels and to determine the effect of JTT-302 on lipid parameters and CETP activity and mass.

Condition or disease Intervention/treatment Phase
Dyslipidemia Drug: JTT-302 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 103 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Eight Week, Open-label Extension Study Evaluating the Safety of JTT-302 Administered Once Daily in Subjects With Low HDL-C Levels Who Have Completed the Treatment Phase of Study AT302-U-06-003
Study Start Date : January 2007
Actual Primary Completion Date : March 2008
Actual Study Completion Date : March 2008

Arm Intervention/treatment
Experimental: 1
JTT-302, 400 mg
Drug: JTT-302
JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal

Primary Outcome Measures :
  1. Evaluate the safety profile of JTT-302 when administered for 8 weeks or 12 weeks [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Percent change and change from baseline after four, eight or 12 weeks exposure to JTT-302 in Lipid Parameters [ Time Frame: 4, 8 or 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have successfully completed the 4-week treatment period of study AT302-U-06-003

Exclusion Criteria:

  • Females who are pregnant or lactating, and females of child bearing potential who are not using an effective method of contraception
  • Use of Cytochrome P450 3A4 inducers or inhibitors, as defined in the protocol
  • Subjects who cannot follow the prescription and OTC medication restrictions defined in the protocol
  • Flu-shots not permitted during the study, including the follow-up period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00748852

United States, California
Santa Ana, California, United States
Sponsors and Collaborators
Akros Pharma Inc.

Responsible Party: Akros Pharma Inc. Identifier: NCT00748852     History of Changes
Other Study ID Numbers: AT302-U-06-004
First Posted: September 9, 2008    Key Record Dates
Last Update Posted: February 4, 2013
Last Verified: January 2013

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases